Effect of Continuous Positive Airway Pressure on Adiponectin in Patients with Obstructive Sleep Apnea: A Meta-Analysis

• Published in: PloS one Vol. 10; no. 9; p. e0136837
• Main Authors: Chen, Li-Da, Liu, Jian-Nan, Lin, Li, Wu, Zhi, Li, Hao, Ye, Yu-Ming, Xu, Qiao-Zhen, Lin, Qi-Chang
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 14-09-2015; Public Library of Science (PLoS)
• Subjects: Adipocytes; Adiponectin; Adiponectin - blood; Adult; Aged; Apnea; Body mass; Body mass index; Body size; Body weight; Confidence intervals; Continuous positive airway pressure; Continuous Positive Airway Pressure - adverse effects; Disease; Female; Gene expression; Hospitals; Humans; Kinases; Male; Medical ethics; Medical research; Medicine; Meta-analysis; Metabolism; Middle Aged; Mortality; Obesity; Observational studies; Patients; Pressure; Researchers; Respiratory therapy; Respiratory tract; Sleep; Sleep apnea; Sleep Apnea, Obstructive - blood; Sleep Apnea, Obstructive - therapy; Sleep disorders; Statistical analysis; Studies; Subgroups; Therapy; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0136837

Obstructive sleep apnea (OSA) has been suggested to be associated with low levels of adiponectin. Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA; however, previous studies assessing the effect of CPAP on adiponectin in patients with OSA yielded conflicting results. The present meta-analysis was performed to determine whether CPAP therapy could increase adiponectin levels.
Two reviewers independently searched PubMed, Cochrane library, Embase and Web of Science before February 2015. Information on characteristics of subjects, study design and pre- and post-CPAP treatment of serum adiponectin was extracted for analysis. Standardized mean difference (SMD) was used to analyze the summary estimates for CPAP therapy.
Eleven studies involving 240 patients were included in this meta-analysis, including ten observational studies and one randomized controlled study. The meta-analysis showed that there was no change of adiponectin levels before and after CPAP treatment in OSA patients (SMD = 0.059, 95% confidence interval (CI) = -0.250 to 0.368, z = 0.37, p = 0.710). Subgroup analyses indicated that the results were not affected by age, baseline body mass index, severity of OSA, CPAP therapy duration, sample size and racial differences.
This meta-analysis suggested that CPAP therapy has no impact on adiponectin in OSA patients, without significant changes in body weight. Further large-scale, well-designed long-term interventional investigations are needed to clarify this issue.